PMID- 28641170 OWN - NLM STAT- MEDLINE DCOM- 20180326 LR - 20181202 IS - 1525-5069 (Electronic) IS - 1525-5050 (Linking) VI - 73 DP - 2017 Aug TI - Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study. PG - 173-179 LID - S1525-5050(17)30052-5 [pii] LID - 10.1016/j.yebeh.2017.02.028 [doi] AB - Eslicarbazepine acetate (ESL, Aptiom) is a once-daily anticonvulsant, approved as adjunctive treatment of partial-onset seizures (POS). Historical-controlled trials investigating the use of ESL as monotherapy have demonstrated a favorable efficacy and tolerability profile in patients with POS. This prospective, non-interventional study recruited POS patients in 17 hospitals in Spain. After a 3-month baseline period, ESL therapy was initiated as 400mg QD and up-titrated to an optimal maintenance dose based on clinical response and tolerance. The incidence of seizures was assessed via seizure calendars and the nature and severity of adverse events (AEs) were also recorded. A total of 117 patients (aged 9-87years) enrolled in the study and were treated with ESL at either 400mg/day (3.4% patients), 800mg/day (61% patients), 1200mg/day (27.1% patients) or 1600mg/day (8.5% patients). At 3months, 82.0% (n=72) of patients achieved a >/=50% reduction in seizure frequency, compared to 79.7% (n=67) of patients at 6months and 83.0% (n=49) at 12months. Patients who suffered secondary generalized tonic-clonic (SGTC) seizures had seizure-free rates of 71% (n=27), 69.6% (n=29), and 72.7% (n=16) at 3, 6, and 12months, respectively. Overall, 18 patients (15.3%) reported AEs of instability and dizziness (n=9), somnolence (n=3), mild hyponatremia (n=3), headache (n=1), hypertriglyceridemia (n=1), and allergic reaction (n=1), which caused ESL discontinuation of ESL treatment. ESL is effective and well tolerated as monotherapy for patients with POS, which supports previous findings. Early use is supported by its frequent use as monotherapy in this study and lack of severe side effects. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Toledano, Rafael AU - Toledano R AD - Hospital Universitario Ramon y Cajal, Servicio de Neurologia, Madrid, Spain; Hospital Ruber Internacional, Servicio de Neurologia, Madrid, Spain. FAU - Jovel, Camilo Espinosa AU - Jovel CE AD - Hospital Occidente de Kennedy, Servicio de Neurologia, Bogota, Colombia. FAU - Jimenez-Huete, Adolfo AU - Jimenez-Huete A AD - Hospital Ruber Internacional, Servicio de Neurologia, Madrid, Spain. FAU - Bayarri, Pau Giner AU - Bayarri PG AD - Hospital Universitario Doctor Peset, Servicio de Neurologia, Valencia, Spain. FAU - Campos, Dulce AU - Campos D AD - Hospital Clinico Universitario de Valladolid, Servicio de Neurologia, Valladolid, Spain. FAU - Gomariz, Elena Lopez AU - Gomariz EL AD - Hospital Publico Lluis Alcanyis De Xativa, Servicio de Neurologia, Valencia, Spain. FAU - Giraldez, Beatriz Gonzalez AU - Giraldez BG AD - Hospital Universitario Fundacion Jimenez Diaz, Servicio de Neurologia, Madrid, Spain. FAU - Garcia-Morales, Irene AU - Garcia-Morales I AD - Hospital Ruber Internacional, Servicio de Neurologia, Madrid, Spain; Hospital Universitario Clinico San Carlos, Servicio de Neurologia, Madrid, Spain. FAU - Falip, Merce AU - Falip M AD - Hospital Universitario de Bellvitge, Servicio de Neurologia, Barcelona, Spain. FAU - Agredano, Paula Martinez AU - Agredano PM AD - Hospital Universitario Virgen del Rocio, Servicio de Neurologia, Sevilla, Spain. FAU - Palao, Susana AU - Palao S AD - Hospital General Universitario de Alicante, Servicio de Neurologia, Alicante, Spain. FAU - Prior, Maria Jose Aguilar Amat AU - Prior MJAA AD - Hospital Universitario La Paz, Servicio de Neurologia, Madrid, Spain. FAU - Pascual, Maria Rosa Querol AU - Pascual MRQ AD - Complejo Universitario Hospital Infanta Cristina, Servicio de Neurologia, Badajoz, Spain. FAU - Navacerrada, Francisco Jose AU - Navacerrada FJ AD - Hospital Universitario del Sureste, Servicio de Neurologia, Madrid, Spain. FAU - Gonzalez, Francisco Javier Lopez AU - Gonzalez FJL AD - Hospital Universitario de Santiago de Compostela, Servicio de Neurologia, Santiago de Compostela, Spain. FAU - Ojeda, Joaquin AU - Ojeda J AD - Hospital Universitario Infanta Sofia, Servicio de Neurologia, Madrid, Spain. FAU - Saez, Aranzazu Alfaro AU - Saez AA AD - CIBER-BBN, Madrid, Spain; Hospital Vega Baja de Orihuela, Seccion de Neurologia, Alicante, Spain. FAU - Bermejo, Pedro Emilio AU - Bermejo PE AD - Hospital Universitario Puerta de Hierro, Servicio de Neurologia, Madrid, Spain. FAU - Gil-Nagel, Antonio AU - Gil-Nagel A AD - Hospital Universitario Ramon y Cajal, Servicio de Neurologia, Madrid, Spain. Electronic address: agnagel@ruberinternacional.es. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20170620 PL - United States TA - Epilepsy Behav JT - Epilepsy & behavior : E&B JID - 100892858 RN - 0 (Anticonvulsants) RN - 0 (Dibenzazepines) RN - BEA68ZVB2K (eslicarbazepine acetate) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Anticonvulsants/adverse effects/*therapeutic use MH - Child MH - Depression/chemically induced MH - Dibenzazepines/adverse effects/*therapeutic use MH - Dizziness/chemically induced MH - Female MH - Headache/chemically induced MH - Humans MH - Male MH - Middle Aged MH - Prospective Studies MH - Seizures/*drug therapy MH - Spain MH - Treatment Outcome MH - Young Adult OTO - NOTNLM OT - Antiepileptic drugs OT - Epilepsy OT - Eslicarbazepine acetate OT - Multicenter studies OT - Partial-onset seizures (POS) EDAT- 2017/06/24 06:00 MHDA- 2018/03/27 06:00 CRDT- 2017/06/23 06:00 PHST- 2017/01/16 00:00 [received] PHST- 2017/02/14 00:00 [revised] PHST- 2017/02/15 00:00 [accepted] PHST- 2017/06/24 06:00 [pubmed] PHST- 2018/03/27 06:00 [medline] PHST- 2017/06/23 06:00 [entrez] AID - S1525-5050(17)30052-5 [pii] AID - 10.1016/j.yebeh.2017.02.028 [doi] PST - ppublish SO - Epilepsy Behav. 2017 Aug;73:173-179. doi: 10.1016/j.yebeh.2017.02.028. Epub 2017 Jun 20.